Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

(1985): Job JC+, Arch Fr Pediatr 42(9), 765
(1983): Guest G+, Arch Fr Pediatr 40(6), 453
Toxic epidermal necrolysis
(2003): Hall VC+, JAmAcadDermatol48(4), 548 (with
thalidomide)
Mucosal
Oral candidiasis
(2001): Hardy JR+, Palliat Med 15(1), 3
(1983): Hanks GW+, Postgrad Med J 59(697), 702
Hair
Hair – alopecia
(2003): Jain R+, JDermatol30(10), 713 (9%) (with
cyclophosphamide)
Hair – hirsutism
(1997): Borgna-Pignatti+, JPediatr130(1), 13
Hair – hypertrichosis
(2006): Mentink LF+, Arch Dermatol 142(5), 570
Eyes
Cataract
(2003): Jain R+, JDermatol30(10), 713 (with cyclophosphamide)
(1994): Zheng Y+, Yan Ke Xue Bao 10(2), 102
(1989): Mohan R+, Indian J Ophthalmol 37(1), 13
(1986): Bluming AZ+, J Clin Oncol 4(2), 221
Glaucoma
(2006): Mentink LF+, Arch Dermatol 142(5), 570
(2003): Jain R+, JDermatol30(10), 713 (3 cases) (with
cyclophosphamide)
(1999): Tan DT+, Ophthalmology 106(2), 223
(1995): Kong L+, Yan Ke Xue Bao 11(1), 53
(1993): Aggarwal RK+, Eye 7, 664
(1993): Kong LX, Zhonghua Yan Ke Za Zhi 29(3), 151
(1989): Mohan R+, Indian J Ophthalmol 37(1), 13
Ocular hypertension
(2001): Dinning WJ+, Ophthalmology 108(10), 1715
(2000): Ng JS+, Ophthalmology 107(11), 2097
(1999): Deng Y+, HuaXiYiKeDaXueXueBao30(2), 205
Ocular keratitis
(2003): Davidson RS+, JGlaucoma12(1), 23
Ocular pain
(1999): Deng Y+, HuaXiYiKeDaXueXueBao30(2), 205
(1997): Kwok AK+, Ophthalmology 104(12), 2112
(1995): Clark AF+, Invest Ophthalmol Vis Sci 36(2), 478
(1986): Kass M+, Am J Ophthalmol 102(2), 159
(1984): Stewart RH+, Curr Eye Res 3(6), 835
Retinopathy
(1995): Ramanathan R+, JPerinatol15(3), 178 (12 cases)
Vision blurred
(2003): Jain R+, JDermatol30(10), 713 (9%) (with
cyclophosphamide)
Visual halos
(1999): Deng Y+, HuaXiYiKeDaXueXueBao30(2), 205
Other
Abdominal pain (sic)
(1997): Borgna-Pignatti C+, JPediatr130(1), 13
Adverse effects
(2005): Richardson PG+, NEnglJMed352(24), 2487 (60%)
(2004): Borst F+, Ann Hematol 83(12), 764
(2004): May C+, Monaldi Arch Chest Dis 61(3), 162
(2004): Odd DE+, J Paediatr Child Health 40(5-6), 282
(2004): Palladini G+, Blood 103(8), 2936 (11%) (with melphalan)
(1998): Yeh TF+, Pediatrics 101(5), E7
(1986): Garden JM+, Arch Dermatol 122(9), 1007
Anaphylactoid reactions/Anaphylaxis
(1997): Figueredo E+, Allergy 52(8), 877
Candidiasis
(2002): Pera A+, JPerinatol22(3), 204
DEXCHLORPHENIRAMINE 171
Death
(1994): Malik IA+, South Med J 87(3), 409
(1992): Heimdal K+, J Neurooncol 12(2), 141
(1992): O’Neil EA+, Arch Dis Child 67(1), 10
(1991): Friedenberg WR+, Am J Hematol 36(3), 171
(1990): Ferrara TB+, JPerinatol10(2), 137
Embolia cutis medicamentosa (Nicolau syndrome)
(1997): Kohler LD+, Int J Dermatol 36(3), 197 (with diclofenac)
Fever
(1997): McIntyre PB+, JAMA 278(11), 925
(1994): Pichard E+, Isr J Med Sci 30(5-6), 408
Hypersensitivity
(1993): Chan AT, BMJ 306, 109
(1993): Williams WR, BMJ 306(6877), 585
(1986): Baldinger J+, Ann Ophthalmol eact(3), 95 (with
polymyxin B/neomycin)
Infections
(2004): Mantadakis E+, Pediatr Hematol Oncol 21(1), 27
(2003): Belgaumi AF+, Cancer 97(11), 2898 (36%)
(1999): Stoll BJ+, Pediatrics 104(5), e63
(1998): Hari P+, Indian J Pediatr 65(4), 557
(1998): Papile LA+, NEnglJMed338(16), 1112
(1998): Thomas MC+, Int J Clin Pract 52(7), 520
(1995): Koehler PJ, Anticancer Drugs 6(1), 19
(1994): Keogh P+, Neurosurgery 34(2), 364
(1994): Sharada B+, Rheumatol Int 14(3), 91
(1991): Friedenberg WR+, Am J Hematol 36(3), 171
(1990): Ferrara TB+, JPerinatol10(2), 137
(1990): Karnik R+, Wien Klin Wochenschr 102(1), 1
(1990): Ng PC+, Arch Dis Child 65(1 Spec No), 54
(1985): Moskopp D, Neurochirurgia (Stuttg) 28(3), 147
(1983): Hanks GW+, Postgrad Med J 59(697), 702
(1980): West BC+, Am J Ophthalmol 89(6), 854
Myalgia/Myositis/Myopathy/Myotoxicity
(2006): Mentink LF+, Arch Dermatol 142(5), 570
(2005): Richardson PG+, NEnglJMed352(24), 2487
(2001): Hardy JR+, Palliat Med 15(1), 3
(1995): Koehler PJ, Anticancer Drugs 6(1), 19
(1991): Dropcho EJ+, Neurology 41(8), 1235
Side effects (sic)
(2001): Hamon I+, J Gynecol Obstet Biol Reprod (Paris) 30(6), S50
(1997): Kuhne T+, JPediatr130(1), 17
(1996): Ralls JE, Aust Fam Physician 25(5), 713
Toxicity (sic)
(2003): Belgaumi AF+, Cancer 97(11), 2898 (with daunomycin)
DEXCHLORPHENIRAMINE
Trade names: Delamin; Poladex; Polaramin; Polaramine;
Polaronil; Polazit; Tanafed (First Horizon); Trenolone
Indications: Allergic rhinitis, urticaria
Category: Histamine H1 receptor antagonist
Half-life: 20–24 hours
Clinically important, potentially hazardous interactions
with: barbiturates, chloral hydrate, ethchlorvynol, glutethimide,
phenothiazines, zolpidem
Reactions
Skin
Angioedema (